Effects of Shin'iseihaito in asthma patients with upper airway disease

Effects of Shin'iseihaito in asthma patients with upper airway disease - Effects of Shin'iseihaito in asthma patients with upper airway disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016621

Enrollment

Registered

2015-02-25

Start date

2015-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Shin&#39

iseihaito(2.5g/package) 3 packages a day for 12weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Among outpatients of bronchial asthma, all of the following criteria was required for enrollment. (1)age 15 years-old or more (2)less than 24 points of ACT score (3)with upper airway deisease

Exclusion criteria

Exclusion criteria: (1) hypersensitivity of the harbal medicine included in Shin'iseihaito. (2) interstitial pneumonia (3) Liver dysfunction; more than 2.0mg/dl of T-Bil or more than 100IU/l of transaminase. (4) treated with systemic steroid or anti-IgE antibody or the harbal medicine included in Shin'iseihaito. (5) pregnant or nursing or planning of pregnancy. (6) the change of medication or surgical treatment are scheduled during study period.

Design outcomes

Primary

Measure	Time frame
The change of ACT score 12 weeks after the introduction of Shin'iseihaito.	—

Countries

Japan

Contacts

Public ContactYuko Katayama

Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital Respiratory Disease Center

yk-katayama@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Effects of Shin&#39;iseihaito in asthma patients with upper airway disease